reSET-O® Non-Monetary CM N/A

GUDID 10196439000036

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives to patients based on the Contingency management system.

PEAR THERAPEUTICS, INC.

Psychological assessment software

• Primary Device ID: 10196439000036
• NIH Device Record Key: c190d491-d50b-4d99-a6e7-2e7635624ebf
• Commercial Distribution Status: In Commercial Distribution
• Brand Name: reSET-O® Non-Monetary CM
• Version Model Number: 1
• Catalog Number: N/A
• Company DUNS: 079705123
• Company Name: PEAR THERAPEUTICS, INC.
• Device Count: 1
• DM Exempt: false
• Pre-market Exempt: false
• MRI Safety Status: Labeling does not contain MRI Safety Information
• Human Cell/Tissue Product: false
• Device Kit: false
• Device Combination Product: false
• Single Use: false
• Lot Batch: true
• Serial Number: false
• Manufacturing Date: false
• Expiration Date: false
• Donation Id Number: false
• Contains Natural Rubber Latex: false
• Labeled No Natural Rubber Latex: false
• RX Perscription: true
• OTC Over-The-Counter: false

Device Identifiers

Device Issuing Agency	Device ID
GS1	10196439000036 [Primary]

FDA Pre-market Approvals/Notifications & deNovo

• Premarket Notification: K173681

FDA Product Code

• PWE: Computerized Behavioral Therapy Device For Psychiatric Disorders

Sterilization

• Steralize Prior To Use: false
• Device Is Sterile: false

Device Entry Metadata

• Public Version Status: New
• Device Record Status: Published
• Public Version Number: 1
• Public Version Date: 2022-06-16
• Device Publish Date: 2022-06-08

Devices Manufactured by PEAR THERAPEUTICS, INC.

• 10196439000005 - reSET®: 2022-06-16 reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 yea
• 10196439000012 - reSET® Non-Monetary CM: 2022-06-16 reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 yea
• 10196439000029 - reSET-O®: 2022-06-16 reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognit
• 10196439000036 - reSET-O® Non-Monetary CM: 2022-06-16reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic. This configuration of reSET-O is intended to provide virtual incentives to patients based on the Contingency management system.
• 10196439000036 - reSET-O® Non-Monetary CM: 2022-06-16 reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognit
• 10851580008255 - Somryst™: 2020-09-17 Somryst is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (Cognitive Behavioral Ther
• 10851580008019 - reSET®: 2020-07-23 "reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 ye
• 10851580008040 - reSET®: 2020-07-23 reSET Web Dashboard is available using an internet browser. reSET is intended to provide cognitive behavioral therapy, as an adj
• 10851580008132 - reSET® Introductory Access Limited Version: 2020-07-23 reSET® is a prescription-only digital therapy intended to deliver cognitive behavioral therapy (CBT) to patients with substance